Drug Profile
REN 1654
Alternative Names: CPI 1189; REN 1189Latest Information Update: 01 May 2007
Price :
$50
*
At a glance
- Originator Renovis
- Class Analgesics; Neuroprotectants; Small molecules
- Mechanism of Action Free radical scavengers; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dementia; Inflammatory bowel diseases; Postherpetic neuralgia; Sciatica
Most Recent Events
- 25 Aug 2005 Discontinued - Phase-II for Sciatica in USA (PO)
- 25 Aug 2005 Preclinical trials in Sciatica in USA (unspecified route)
- 07 Mar 2005 Discontinued - Phase-II for Postherpetic neuralgia in USA (PO)